Vanda Pharmaceuticals (NASDAQ: VNDA) recently resolved its patent litigation against Apotex regarding Apotex’s Abbreviated New Drug Application seeking approval of its generic version of Vanda’s Fanapt® (iloperidone). Under a licensing agreement, Vanda has granted Apotex a non-exclusive license to manufacture and commercialize its version of Fanapt® in the U.S., effective November 2, 2027. Fanapt® in 2009 was approved by the FDA for the treatment of schizophrenia in adults. In 2012, the drug was approved for marketing in Israel and Argentina.
To view the full press release, visit: http://nnw.fm/XSt0U
About Vanda Pharmaceuticals Inc.
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net